Search

Your search keyword '"Efstathiou, Jason A."' showing total 287 results
Start Over Author "Efstathiou, Jason A." Publication Year Range Last 3 years
287 results on '"Efstathiou, Jason A."'

1. Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System

Author

Panebianco, Valeria, Briganti, Alberto, Boellaard, Thierry N., Catto, James, Comperat, Eva, Efstathiou, Jason, van der Heijden, Antoine G., Giannarini, Gianluca, Girometti, Rossano, Mertens, Laura, Takeuchi, Mitsuru, Muglia, Valdair F., Narumi, Yoshifumi, Novara, Giacomo, Pecoraro, Martina, Roupret, Morgan, Sanguedolce, Francesco, Santini, Daniele, Shariat, Shahrokh F., Simone, Giuseppe, Vargas, Hebert A., Woo, Sungmin, Barentsz, Jelle, and Witjes, J. Alfred

Published
2024
Full Text
View/download PDF

2. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.

Author

Roy, Soumyajit, Romero, Tahmineh, Michalski, Jeff, Feng, Felix, Efstathiou, Jason, Lawton, Colleen, Bolla, Michel, Maingon, Philippe, de Reijke, Theo, Joseph, David, Ong, Wee, Sydes, Matthew, Dearnaley, David, Tree, Alison, Carrier, Nathalie, Nabid, Abdenour, Souhami, Luis, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen, Maldonado, Xavier, Reiter, Robert, Nickols, Nicholas, Ma, T, Farrell, Matthew, Neilsen, Beth, Juarez, Jesus, Deng, Jie, Vangala, Sitaram, Avril, Norbert, Jia, Angela, Zaorsky, Nicholas, Sun, Yilun, Spratt, Daniel, Kishan, Amar, Rettig, Matthew, Steinberg, Michael, and Valle, Luca

Subjects
Male, Humans, Prostate, Prostatic Neoplasms, Androgen Antagonists, Prostate-Specific Antigen, Adenocarcinoma
Abstract

PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. MATERIALS AND METHODS: Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed using the Prentice criteria (including landmark analyses) and the two-stage meta-analytic approach (estimating Kendalls tau and the R2). Biochemical recurrence-free survival (BCRFS, time from random assignment to BCR or any death) and time to BCR (TTBCR, time from random assignment to BCR or cancer-specific deaths censoring for noncancer-related deaths) were assessed. RESULTS: Overall, 10,741 patients were included. Dose escalation, addition of short-term ADT, and prolongation of ADT duration significantly improved BCR (hazard ratio [HR], 0.71 [95% CI, 0.63 to 0.79]; HR, 0.53 [95% CI, 0.48 to 0.59]; and HR, 0.54 [95% CI, 0.48 to 0.61], respectively). Adding short-term ADT (HR, 0.91 [95% CI, 0.84 to 0.99]) and prolonging ADT (HR, 0.86 [95% CI, 0.78 to 0.94]) significantly improved OS, whereas dose escalation did not (HR, 0.98 [95% CI, 0.87 to 1.11]). BCR at 48 months was associated with inferior OS in all three groups (HR, 2.46 [95% CI, 2.08 to 2.92]; HR, 1.51 [95% CI, 1.35 to 1.70]; and HR, 2.31 [95% CI, 2.04 to 2.61], respectively). However, after adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95% CI, 0.96 to 1.27]; HR, 0.96 [95% CI, 0.87 to 1.06] and 1.00 [95% CI, 0.90 to 1.12], respectively). The patient-level correlation (Kendalls tau) for BCRFS and OS ranged between 0.59 and 0.69, and that for TTBCR and OS ranged between 0.23 and 0.41. The R2 values for trial-level correlation of the treatment effect on BCRFS and TTBCR with that on OS were 0.563 and 0.160, respectively. CONCLUSION: BCRFS and TTBCR are prognostic but failed to satisfy all surrogacy criteria. Strength of correlation was greater when noncancer-related deaths were considered events.

Published
2023

3. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

Author

Martin, Ting, Sun, Yilun, Malone, Shawn, Roach, Mack, Dearnaley, David, Pisansky, Thomas M, Feng, Felix Y, Sandler, Howard M, Efstathiou, Jason A, Syndikus, Isabel, Hall, Emma C, Tree, Alison C, Sydes, Matthew R, Cruickshank, Claire, Roy, Soumyajit, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Romero, Tahmineh, Steinberg, Michael L, Valle, Luca F, Rettig, Matthew B, Nickols, Nicholas G, Shoag, Jonathan E, Reiter, Robert E, Zaorsky, Nicholas G, Jia, Angela Y, Garcia, Jorge A, Spratt, Daniel E, Kishan, Amar U, and Investigators, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate Consortium

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Research, Patient Safety, Urologic Diseases, Cancer, Prostate Cancer, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Good Health and Well Being, Male, Humans, Prostatic Neoplasms, Androgen Antagonists, Androgens, Randomized Controlled Trials as Topic, Prostate-Specific Antigen, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).Materials and methodsIndividual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer-specific mortality.ResultsOverall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points (P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer-specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT.ConclusionADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.

Published
2023

4. Bladder cancer

Author

Dyrskjøt, Lars, Hansel, Donna E., Efstathiou, Jason A., Knowles, Margaret A., Galsky, Matthew D., Teoh, Jeremy, and Theodorescu, Dan

Published
2023
Full Text
View/download PDF

5. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial

Author

Jones, Christopher U, Pugh, Stephanie L, Sandler, Howard M, Chetner, Michael P, Amin, Mahul B, Bruner, Deborah W, Zietman, Anthony L, Den, Robert B, Leibenhaut, Mark H, Longo, John M, Bahary, Jean-Paul, Rosenthal, Seth A, Souhami, Luis, Michalski, Jeff M, Hartford, Alan C, Amin, Pradip P, Roach, Mack, Yee, Don, Efstathiou, Jason A, Rodgers, Joseph P, Feng, Felix Y, and Shipley, William U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Urologic Diseases, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Androgen Antagonists, Androgens, Follow-Up Studies, Humans, Male, Prostate-Specific Antigen, Prostatic Neoplasms, Other Physical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeFor men with localized prostate cancer, NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9408 demonstrated that adding short-term androgen deprivation therapy (ADT) to radiation therapy (RT) improved the primary endpoint of overall survival (OS) and improved disease-specific mortality (DSM), biochemical failure (BF), local progression, and freedom from distant metastases (DM). This study was performed to determine whether the short-term ADT continued to improve OS, DSM, BF, and freedom from DM with longer follow-up.Methods and materialsFrom 1994 to 2001, NRG/RTOG 9408 randomized 2028 men from 212 North American institutions with T1b-T2b, N0 prostate adenocarcinoma and prostate-specific antigen (PSA) ≤20ng/mL to RT alone or RT plus short-term ADT. Patients were stratified by PSA, tumor grade, and surgical versus clinical nodal staging. ADT was flutamide with either goserelin or leuprolide for 4 months. Prostate RT (66.6 Gy) was started after 2 months. OS was calculated at the date of death from any cause or at last follow-up. Secondary endpoints were DSM, BF, local progression, and DM. Acute and late toxic effects were assessed using RTOG toxicity scales.ResultsMedian follow-up in surviving patients was 14.8 years (range, 0.16-21.98). The 10-year and 18-year OS was 56% and 23%, respectively, with RT alone versus 63% and 23% with combined therapy (HR 0.94; 95% confidence interval [CI], 0.85-1.05; P = .94). The hazards were not proportional (P = .003). Estimated restricted mean survival time at 18 years was 11.8 years (95% CI, 11.4-12.1) with combined therapy versus 11.3 years with RT alone (95% CI, 10.9-11.6; P = .05). The 10-year and 18-year DSM was 7% and 14%, respectively, with RT alone versus 3% and 8% with combined therapy (HR 0.56; 95% CI, 0.41-0.75; P < .01). DM and BF favored combined therapy at 18 years. Rates of late grade ≥3 hepatic, gastrointestinal, and genitourinary toxicity were ≤1%, 3%, and 8%, respectively, with combined therapy versus ≤1%, 2%, and 5% with RT alone.ConclusionsFurther follow-up demonstrates that OS converges at approximately 15 years, by which point the administration of 4 months of ADT had conferred an estimated additional 6 months of life.

Published
2022

6. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202

Author

Mak, Kimberley S., Scannell Bryan, Molly, Dignam, James J., Shipley, William U., Lin, Yue, Peters, Christopher A., Gore, Elizabeth M., Rosenthal, Seth A., Zeitzer, Kenneth L., D'Souza, David P., Horwitz, Eric M., Pisansky, Thomas M., Maier, Jordan M., Chafe, Susan M., Robin, Tyler P., Roach, Mack, III, Tran, Phuoc T., Souhami, Luis, Michalski, Jeff M., Hartford, Alan C., Feng, Felix Y., Sandler, Howard M., and Efstathiou, Jason A.

Published
2024
Full Text
View/download PDF

7. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation

Author

Dahl, Douglas M., Karrison, Theodore G., Michaelson, M. Dror, Pham, Huong T., Wu, Chin-Lee, Swanson, Gregory P., Shipley, William U., Vuky, Jacqueline, Lee, R. Jeffrey, Zietman, Anthony L., Souhami, Luis, Chang, Brian K., Deming, Richard L., Ellerton, John A., Sandler, Howard M., Rodgers, Joseph P., Feng, Felix Y., and Efstathiou, Jason A.

Published
2024
Full Text
View/download PDF

8. Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial

Author

Coen, John J., Rodgers, Joseph P., Saylor, Philip J., Lee, Cheryl T., Wu, Chin-Lee, Parker, William, Lautenschlaeger, Tim, Zietman, Anthony L., Efstathiou, Jason, Jani, Ashesh B., Kucuk, Omer, Souhami, Luis, Pugh, Stephanie L., Sandler, Howard M., and Shipley, William U.

Published
2024
Full Text
View/download PDF

10. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

Author

Alfred Witjes, J., Max Bruins, Harman, Carrión, Albert, Cathomas, Richard, Compérat, Eva, Efstathiou, Jason A., Fietkau, Rainer, Gakis, Georgios, Lorch, Anja, Martini, Alberto, Mertens, Laura S., Meijer, Richard P., Milowsky, Matthew I., Neuzillet, Yann, Panebianco, Valeria, Redlef, John, Rink, Michael, Rouanne, Mathieu, Thalmann, George N., Sæbjørnsen, Sæbjørn, Veskimäe, Erik, and van der Heijden, Antoine G.

Published
2024
Full Text
View/download PDF

12. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial

Author

Spratt, Daniel E., Liu, Vinnie Y.T., Michalski, Jeff, Davicioni, Elai, Berlin, Alejandro, Simko, Jeffry P., Efstathiou, Jason A., Tran, Phuoc T., Sandler, Howard M., Hall, William A., Thompson, Darby J.S., Parliament, Matthew B., Dayes, Ian S., Correa, Rohann Jonathan Mark, Robertson, John M., Gore, Elizabeth M., Doncals, Desiree E., Vigneault, Eric, Souhami, Luis, Karrison, Theodore G., and Feng, Felix Y.

Published
2023
Full Text
View/download PDF

13. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Author

Lukka, Himanshu R., Deshmukh, Snehal, Bruner, Deborah W., Bahary, Jean-Paul, Lawton, Colleen A.F., Efstathiou, Jason A., Kudchadker, Rajat J., Ponsky, Lee E., Seaward, Samantha A., Dayes, Ian S., Gopaul, Darindra D., Michalski, Jeff M., Delouya, Guila, Kaplan, Irving D., Horwitz, Eric M., Roach, Mack, III, Feng, Felix Y., Pugh, Stephanie L., Sandler, Howard M., and Kachnic, Lisa A.

Published
2023
Full Text
View/download PDF

14. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials

Author

Nguyen, Paul L., Huang, Huei-Chung (Rebecca), Spratt, Daniel E., Davicioni, Elai, Sandler, Howard M., Shipley, William U., Efstathiou, Jason A., Simko, Jeffry P., Pollack, Alan, Dicker, Adam P., Roach, Mack, Rosenthal, Seth A., Zeitzer, Kenneth L., Mendez, Lucas C., Hartford, Alan C., Hall, William A., Desai, Anand B., Rabinovitch, Rachel A., Peters, Christopher A., Rodgers, Joseph P., Tran, Phuoc, and Feng, Felix Y.

Published
2023
Full Text
View/download PDF

15. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs

Author

Guo, Hongshan, Vuille, Joanna A., Wittner, Ben S., Lachtara, Emily M., Hou, Yu, Lin, Maoxuan, Zhao, Ting, Raman, Ayush T., Russell, Hunter C., Reeves, Brittany A., Pleskow, Haley M., Wu, Chin-Lee, Gnirke, Andreas, Meissner, Alexander, Efstathiou, Jason A., Lee, Richard J., Toner, Mehmet, Aryee, Martin J., Lawrence, Michael S., Miyamoto, David T., Maheswaran, Shyamala, and Haber, Daniel A.

Published
2023
Full Text
View/download PDF

16. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

Author

Zlotta, Alexandre R, Ballas, Leslie K, Niemierko, Andrzej, Lajkosz, Katherine, Kuk, Cynthia, Miranda, Gus, Drumm, Michael, Mari, Andrea, Thio, Ethan, Fleshner, Neil E, Kulkarni, Girish S, Jewett, Michael A S, Bristow, Robert G, Catton, Charles, Berlin, Alejandro, Sridhar, Srikala S, Schuckman, Anne, Feldman, Adam S, Wszolek, Matthew, Dahl, Douglas M, Lee, Richard J, Saylor, Philip J, Michaelson, M Dror, Miyamoto, David T, Zietman, Anthony, Shipley, William, Chung, Peter, Daneshmand, Siamak, and Efstathiou, Jason A

Published
2023
Full Text
View/download PDF

17. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

Author

Hahn, Noah M., O'Donnell, Michael A., Efstathiou, Jason A., Zahurak, Marianna, Rosner, Gary L., Smith, Jeff, Kates, Max R., Bivalacqua, Trinity J., Tran, Phuoc T., Song, Daniel Y., Baras, Alex S., Matoso, Andres, Choi, Woonyoung, Smith, Kellie N., Pardoll, Drew M., Marchionni, Luigi, McGuire, Bridget, Grace Phelan, Mary, Johnson, Burles A., III, O'Neal, Tanya, McConkey, David J., Rose, Tracy L., Bjurlin, Marc, Lim, Emerson A., Drake, Charles G., McKiernan, James M., Deutsch, Israel, Anderson, Christopher B., Lamm, Donald L., Geynisman, Daniel M., Plimack, Elizabeth R., Hallman, Mark A., Horwitz, Eric M., Al-Saleem, Essel, Chen, David Y.T., Greenberg, Richard E., Kutikov, Alexander, Guo, Gordon, Masterson, Timothy A., Adra, Nabil, and Kaimakliotis, Hristos Z.

Published
2023
Full Text
View/download PDF

18. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

19. Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415

Author

Bai, Jinbing, Pugh, Stephanie L., Eldridge, Ronald, Yeager, Katherine A., Zhang, Qi, Lee, W. Robert, Shah, Amit B., Dayes, Ian S., D'Souza, David P., Michalski, Jeff M., Efstathiou, Jason A., Longo, John M., Pisansky, Thomas M., Maier, Jordan M., Faria, Sergio L., Desai, Anand B., Seaward, Samantha A., Sandler, Howard M., Cooley, Mary E., and Bruner, Deborah W.

Published
2023
Full Text
View/download PDF

20. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

21. PD42-11 DEVELOPMENT AND VALIDATION OF A MULTIMODAL ARTIFICIAL INTELLIGENCE (MMAI)-DERIVED DIGITAL PATHOLOGY-BASED BIOMARKER PREDICTING METASTASIS FOR RADICAL PROSTATECTOMY PATIENTS WITH BIOCHEMICAL RECURRENCE IN NRG/RTOG TRIALS

Author

Morgan, Todd M., primary, Ren, Yi, additional, Tang, Siyi, additional, Zwerink, Wouter, additional, Chen, Emmalyn, additional, Mitani, Akinori, additional, Huang, Huei-Chung, additional, Simko, Jeffry P., additional, DeVries, Sandy, additional, Shipley, William U., additional, Pollack, Alan, additional, Bowes, David, additional, Martin, André-Guy, additional, Balogh, Alexander G., additional, Michalski, Jeff M., additional, Greenberg, Michael J., additional, Efstathiou, Jason A., additional, Bahary, Jean-Paul, additional, Ross, Ashley, additional, Esteva, Andre, additional, Showalter, Timothy N., additional, Nguyen, Paul L., additional, Hoffman, Karen E., additional, Rodgers, Joseph, additional, Feng, Felix, additional, and Spratt, Daniel E., additional

Published
2024
Full Text
View/download PDF

22. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)

Author

Ma, Ting Martin, Chu, Fang-I, Sandler, Howard, Feng, Felix Y., Efstathiou, Jason A., Jones, Christopher U., Roach, Mack, 3rd, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M., Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David, Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Spratt, Daniel E., and Kishan, Amar U.

Published
2022
Full Text
View/download PDF

24. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline S., Clarke, Noel, Davis, Ian D., de Bono, Johann S., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S., Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Rob E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan P., Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E., Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, and Omlin, Aurelius

Published
2022
Full Text
View/download PDF

25. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium

Author

Kishan, Amar U., Wang, Xiaoyan, Sun, Yilun, Romero, Tahmineh, Michalski, Jeff M., Ma, Ting Martin, Feng, Felix Y., Sandler, Howard M., Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Neven, Anouk, Steigler, Allison, Denham, James W., Joseph, David, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Sydes, Matt R., Dearnaley, David P., Syndikus, Isabel, Tree, Alison C., Incrocci, Luca, Heemsbergen, Wilma D., Pos, Floris J., Zapatero, Almudena, Efstathiou, Jason A., Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Xiang, Michael, Rettig, Matthew B., Reiter, Robert E., Zaorsky, Nicholas G., Ong, Wee Loon, Dess, Robert T., Steinberg, Michael L., Nickols, Nicholas G., Roy, Soumyajit, Garcia, Jorge A., and Spratt, Daniel E.

Published
2022
Full Text
View/download PDF

27. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop

Author

Chang, Elaine, Apolo, Andrea B., Bangs, Rick, Chisolm, Stephanie, Duddalwar, Vinay, Efstathiou, Jason A., Goldberg, Kirsten B., Hansel, Donna E., Kamat, Ashish M., Kluetz, Paul G., Lerner, Seth P., Plimack, Elizabeth, Prowell, Tatiana, Singh, Harpreet, Suzman, Daniel, Yu, Evan Y., Zhang, Hui, Beaver, Julia A., Pazdur, Richard, Weinstock, Chana, and Galsky, Matthew D.

Published
2022
Full Text
View/download PDF

30. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

Author

Kishan, Amar U, Sun, Yilun, Hartman, Holly, Pisansky, Thomas M, Bolla, Michel, Neven, Anouk, Steigler, Allison, Denham, James W, Feng, Felix Y, Zapatero, Almudena, Armstrong, John G, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Dunne, Mary T, Efstathiou, Jason A, Sandler, Howard M, Guerrero, Araceli, Joseph, David, Maingon, Philippe, de Reijke, Theo M, Maldonado, Xavier, Ma, Ting Martin, Romero, Tahmineh, Wang, Xiaoyan, Rettig, Matthew B, Reiter, Robert E, Zaorsky, Nicholas G, Steinberg, Michael L, Nickols, Nicholas G, Jia, Angela Y, Garcia, Jorge A, and Spratt, Daniel E

Published
2022
Full Text
View/download PDF

32. Corrigendum to “European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31]

Author

Alfred Witjes, J., primary, Bruins, Harman Max, additional, Carrión, Albert, additional, Cathomas, Richard, additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Fietkau, Rainer, additional, Gakis, Georgios, additional, Lorch, Anja, additional, Martini, Alberto, additional, Mertens, Laura S., additional, Meijer, Richard P., additional, Milowsky, Matthew I., additional, Neuzillet, Yann, additional, Panebiaco, Valeria, additional, Redlef, John, additional, Rink, Michael, additional, Rouanne, Mathieu, additional, Thalmann, George N., additional, Sæbjørnsen, Sæbjørn, additional, Veskimäe, Erik, additional, Mariappan, Paramananthan, additional, and van der Heijden, Antoine G., additional

Published
2024
Full Text
View/download PDF

33. Clinical Outcomes of De Novo Versus Relapsed Early Metastatic Testicular Seminoma Treated With Contemporary Radiation Therapy

Author

Rosen, Daniel B., primary, Ghosh, Anushka, additional, Niemierko, Andrzej, additional, Beard, Clair J., additional, Ravi, Praful, additional, Tewari, Alok, additional, Sweeney, Christopher, additional, Lee, Richard J., additional, Saylor, Philip, additional, Martin, Neil, additional, Efstathiou, Jason A., additional, Mouw, Kent, additional, and Kamran, Sophia C., additional

Published
2024
Full Text
View/download PDF

38. Supplementary Figure S7 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer

Author

Kamran, Sophia C., primary, Zhou, Yuzhen, primary, Otani, Keisuke, primary, Drumm, Michael, primary, Otani, Yukako, primary, Wu, Shulin, primary, Wu, Chin-Lee, primary, Feldman, Adam S., primary, Wszolek, Matthew, primary, Lee, Richard J., primary, Saylor, Philip J., primary, Lennerz, Jochen, primary, Van Allen, Eliezer, primary, Willers, Henning, primary, Hong, Theodore S., primary, Liu, Yang, primary, Davicioni, Elai, primary, Gibb, Ewan A., primary, Shipley, William U., primary, Mouw, Kent W., primary, Efstathiou, Jason A., primary, and Miyamoto, David T., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer

Author

Kamran, Sophia C., primary, Zhou, Yuzhen, primary, Otani, Keisuke, primary, Drumm, Michael, primary, Otani, Yukako, primary, Wu, Shulin, primary, Wu, Chin-Lee, primary, Feldman, Adam S., primary, Wszolek, Matthew, primary, Lee, Richard J., primary, Saylor, Philip J., primary, Lennerz, Jochen, primary, Van Allen, Eliezer, primary, Willers, Henning, primary, Hong, Theodore S., primary, Liu, Yang, primary, Davicioni, Elai, primary, Gibb, Ewan A., primary, Shipley, William U., primary, Mouw, Kent W., primary, Efstathiou, Jason A., primary, and Miyamoto, David T., primary

Published
2023
Full Text
View/download PDF

40. Data from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer

Author

Kamran, Sophia C., primary, Zhou, Yuzhen, primary, Otani, Keisuke, primary, Drumm, Michael, primary, Otani, Yukako, primary, Wu, Shulin, primary, Wu, Chin-Lee, primary, Feldman, Adam S., primary, Wszolek, Matthew, primary, Lee, Richard J., primary, Saylor, Philip J., primary, Lennerz, Jochen, primary, Van Allen, Eliezer, primary, Willers, Henning, primary, Hong, Theodore S., primary, Liu, Yang, primary, Davicioni, Elai, primary, Gibb, Ewan A., primary, Shipley, William U., primary, Mouw, Kent W., primary, Efstathiou, Jason A., primary, and Miyamoto, David T., primary

Published
2023
Full Text
View/download PDF

41. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

Author

Kamat, Ashish M., primary, Apolo, Andrea B., additional, Babjuk, Marek, additional, Bivalacqua, Trinity J., additional, Black, Peter C., additional, Buckley, Roger, additional, Campbell, Matthew T., additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Grivas, Petros, additional, Gupta, Shilpa, additional, Kurtz, Neil J., additional, Lamm, Donald, additional, Lerner, Seth P., additional, Li, Roger, additional, McConkey, David J., additional, Palou Redorta, Joan, additional, Powles, Thomas, additional, Psutka, Sarah P., additional, Shore, Neal, additional, Steinberg, Gary D., additional, Sylvester, Richard, additional, Witjes, J. Alfred, additional, and Galsky, Matthew D., additional

Published
2023
Full Text
View/download PDF

43. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer

Author

Zhou, Yuzhen, primary, Börcsök, Judit, additional, Adib, Elio, additional, Kamran, Sophia C., additional, Neil, Alexander J., additional, Stawiski, Konrad, additional, Freeman, Dory, additional, Stormoen, Dag Rune, additional, Sztupinszki, Zsofia, additional, Samant, Amruta, additional, Nassar, Amin, additional, Bekele, Raie T., additional, Hanlon, Timothy, additional, Valentine, Henkel, additional, Epstein, Ilana, additional, Sharma, Bijaya, additional, Felt, Kristen, additional, Abbosh, Philip, additional, Wu, Chin-Lee, additional, Efstathiou, Jason A., additional, Miyamoto, David T., additional, Anderson, William, additional, Szallasi, Zoltan, additional, and Mouw, Kent W., additional

Published
2023
Full Text
View/download PDF

44. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer

Author

Kamran, Sophia C., primary, Zhou, Yuzhen, additional, Otani, Keisuke, additional, Drumm, Michael, additional, Otani, Yukako, additional, Wu, Shulin, additional, Wu, Chin-Lee, additional, Feldman, Adam S., additional, Wszolek, Matthew, additional, Lee, Richard J., additional, Saylor, Philip J., additional, Lennerz, Jochen, additional, Van Allen, Eliezer, additional, Willers, Henning, additional, Hong, Theodore S., additional, Liu, Yang, additional, Davicioni, Elai, additional, Gibb, Ewan A., additional, Shipley, William U., additional, Mouw, Kent W., additional, Efstathiou, Jason A., additional, and Miyamoto, David T., additional

Published
2023
Full Text
View/download PDF

45. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

Author

Alfred Witjes, J., primary, Max Bruins, Harman, additional, Carrión, Albert, additional, Cathomas, Richard, additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Fietkau, Rainer, additional, Gakis, Georgios, additional, Lorch, Anja, additional, Martini, Alberto, additional, Mertens, Laura S., additional, Meijer, Richard P., additional, Milowsky, Matthew I., additional, Neuzillet, Yann, additional, Panebianco, Valeria, additional, Redlef, John, additional, Rink, Michael, additional, Rouanne, Mathieu, additional, Thalmann, George N., additional, Sæbjørnsen, Sæbjørn, additional, Veskimäe, Erik, additional, and van der Heijden, Antoine G., additional

Published
2023
Full Text
View/download PDF

47. Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.

Author

Lukka, Himu, Pugh, Stephanie L., Shipley, William U., Major, Pierre, Sartor, A. Oliver, Dayes, Ian S., Bahary, Jean-Paul, Efstathiou, Jason A., Pisansky, Thomas Michael, Zeitzer, Kenneth Lee, Lawton, Colleen Anne, Dess, Robert Timothy, Camarata, Andrew S, Balogh, Alexander G., Souhami, Luis, Rosenthal, Seth A., Seiferheld, Wendy, Feng, Felix Y, and Sandler, Howard M.

Published
2024
Full Text
View/download PDF

49. The Role of Proton Therapy for Prostate Cancer in the Setting of Hip Prosthesis.

Author

Moteabbed, Maryam, Bobić, Mislav, Paganetti, Harald, and Efstathiou, Jason A.

Subjects
HIP surgery, PROSTATE tumors treatment, STATISTICS, RESEARCH, CANCER chemotherapy, RETROSPECTIVE studies, ARTIFICIAL joints, RANDOMIZED controlled trials, PROTON therapy, RESEARCH funding, DESCRIPTIVE statistics, RADIOTHERAPY, DATA analysis, DATA analysis software, RADIATION dosimetry, IMMUNOTHERAPY
Abstract

Simple Summary: As proton therapy evolves and becomes more accessible, it is important to explore its potential value for all patient cases to enable more informed treatment individualization. Currently, external beam radiotherapy for prostate cancer patients with hip prosthesis is limited to photons because traditional proton therapy beams interfere with the implanted hardware. The goal of this study was to investigate the dosimetric feasibility and robustness of novel proton therapy techniques, i.e., proton arc therapy and anterior beam directions for prostate cancer patients with unilateral hip prosthesis. It was demonstrated that proton therapy for prostate cancer in the setting of hip prosthesis is feasible and could potentially reduce the dose to some critical organs and hence reduce toxicities. Purpose: Given that the current standard of proton therapy (PT) for prostate cancer is through bilateral beams, this modality is typically avoided when it comes to treatment of patients with hip prosthesis. The purpose of this study was to evaluate whether novel PT methods, i.e., anterior proton beams and proton arc therapy (PArc), could be feasible options to treat this patient subpopulation. We evaluate PT methods in the context of dosimetry and robustness and compare with standard of practice volumetric modulated arc therapy (VMAT) to explore any potential benefits. Methods: Two PT and one VMAT treatment plans were retrospectively created for 10 patients who participated in a clinical trial with a weekly repeat CT (rCT) imaging component. All plans were robustly optimized and featured: (1) combination anterior oblique and lateral proton beams (AoL), (2) PArc, and (3) VMAT. All patients had hydrogel spacers in place, which enabled safe application of anterior proton beams. The planned dose was 70 Gy (RBE) to the entire prostate gland and 50 Gy (RBE) to the proximal seminal vesicles in 28 fractions. Along with plan dose–volume metrics, robustness to setup and interfractional variations were evaluated using the weekly rCT images. The linear energy transfer (LET)-weighted dose was evaluated for PArc plans to ensure urethra sparing given the typical high-LET region at the end of range. Results: Both PT methods were dosimetrically feasible and provided reduction of some key OAR metrics compared to VMAT except for penile bulb, while providing equally good target coverage. Significant differences in median rectum V35 (22–25%), penile bulb Dmean (5 Gy), rectum V61 (2%), right femoral head Dmean (5 Gy), and bladder V39 (4%) were found between PT and VMAT. All plans were equally robust to variations. LET-weighted dose in urethra was equivalent to the physical dose for PArc plans and hence no added urethral toxicity was expected. Conclusions: PT for treatment of prostate cancer patients with hip prosthesis is feasible and equivalent or potentially superior to VMAT in quality in some cases. The choice of radiotherapy regimen can be personalized based on patient characteristics to achieve the best treatment outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results